Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E W LEWIS

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Canadian Medical Association Journal|July 1, 1985
Selecting a treatment for primary varicose veinsJ Tremblay, E W Lewis, P T Allen
Virology|May 6, 1998
Mechanisms of replication-deficient vaccinia virus/T7 RNA polymerase hybrid expression: effect of T7 RNA polymerase levels and alpha-amanitinK A Engleka, E W Lewis, B H Howard
Journal of Clinical Immunology|September 1, 1986
Immunoregulatory dysfunctions in type I diabetes: natural and antibody-dependent cellular cytotoxic activitiesM P Nair, E W Lewis, S A Schwartz
The Journal of Pharmacology and Experimental Therapeutics|August 8, 1998
The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERGD Rampe, M K Murawsky, J Grau, et al.
Molecular Pharmacology|August 1, 1997
Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heartA E Lacerda, M L Roy, E W Lewis, et al.
Journal of Psychoactive Drugs|October 1, 1994
Anger management and temper control: critical components of posttraumatic stress disorder and substance abuse treatmentP M Reilly, H W Clark, M S Shopshire, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 1, 1994
Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agentsG A Losonsky, A Wolf, R S Schwalbe, et al.
Journal of Pharmacokinetics and Biopharmaceutics|February 1, 1995
Population pharmacokinetics of teicoplanin in patients with endocarditisD K Yu, E Nordbrock, S J Hutcheson, et al.
Biopharmaceutics & Drug Disposition|April 1, 1992
Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteersG A Thompson, J A Smithers, M T Kenny, et al.
Journal of Pharmaceutical Sciences|June 1, 1991
Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humansK K Antony, E W Lewis, M T Kenny, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Canadian Medical Association Journal|July 1, 1985
Selecting a treatment for primary varicose veinsJ Tremblay, E W Lewis, P T Allen
Virology|May 6, 1998
Mechanisms of replication-deficient vaccinia virus/T7 RNA polymerase hybrid expression: effect of T7 RNA polymerase levels and alpha-amanitinK A Engleka, E W Lewis, B H Howard
Journal of Clinical Immunology|September 1, 1986
Immunoregulatory dysfunctions in type I diabetes: natural and antibody-dependent cellular cytotoxic activitiesM P Nair, E W Lewis, S A Schwartz
The Journal of Pharmacology and Experimental Therapeutics|August 8, 1998
The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERGD Rampe, M K Murawsky, J Grau, et al.
Molecular Pharmacology|August 1, 1997
Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heartA E Lacerda, M L Roy, E W Lewis, et al.
Journal of Psychoactive Drugs|October 1, 1994
Anger management and temper control: critical components of posttraumatic stress disorder and substance abuse treatmentP M Reilly, H W Clark, M S Shopshire, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 1, 1994
Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agentsG A Losonsky, A Wolf, R S Schwalbe, et al.
Journal of Pharmacokinetics and Biopharmaceutics|February 1, 1995
Population pharmacokinetics of teicoplanin in patients with endocarditisD K Yu, E Nordbrock, S J Hutcheson, et al.
Biopharmaceutics & Drug Disposition|April 1, 1992
Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteersG A Thompson, J A Smithers, M T Kenny, et al.
Journal of Pharmaceutical Sciences|June 1, 1991
Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humansK K Antony, E W Lewis, M T Kenny, et al.
Pageof 2